Skip to main content
. 2022 Sep 12;15(12):2245–2257. doi: 10.1093/ckj/sfac193

Table 3:

Sub-distribution HRs (95% CI) for fracture risk starting 90 days after dialysis initiation in US patients with ESKD attributed to one of five glomerular diseases, diabetic nephropathy or ADPKD compared with IgA nephropathy.

IgA nephropathy FSGS Membranous nephropathy Lupus nephritis Vasculitis Diabetic nephropathy ADPKD
Composite (any) fracture
 Model 1 ref 1.13 (1.02–1.24) 1.27 (1.13–1.41) 0.84 (0.71–0.97) 1.65 (1.53–1.78) 1.66 (1.56–1.76) 1.63 (1.52–1.73)
 Model 2 ref 1.14 (1.03–1.25) 1.18 (1.04–1.32) 0.88 (0.75–1.01) 1.26 (1.13–1.38) 1.44 (1.34–1.54) 1.39 (1.28–1.49)
 Model 3 ref 1.13 (1.02–1.24) 1.17 (1.03–1.31) 0.87 (0.74–1.01) 1.23 (1.10–1.35) 1.44 (1.33–1.54) 1.37 (1.27–1.48)
 Model 4 ref 1.13 (1.02–1.24) 1.16 (1.02–1.29) 0.86 (0.73–0.99) 1.22 (1.10–1.35) 1.41 (1.31–1.51) 1.38 (1.27–1.49)
 Model 5 ref 1.13 (1.02–1.24) 1.16 (1.02–1.30) 0.85 (0.71–0.98) 1.22 (1.09–1.34) 1.43 (1.33–1.53) 1.37 (1.26–1.48)
 Model 6 ref 1.13 (1.02–1.24) 1.19 (1.06–1.33) 0.88 (0.76–1.02) 1.28 (1.15–1.40) 1.41 (1.31–1.51) 1.39 (1.28–1.50)
Hip fracture
 Model 1 ref 1.08 (0.93–1.24) 1.45 (1.27–1.64) 0.65 (0.46–0.84) 1.94 (1.77–2.11) 1.43 (1.29–1.56) 1.54 (1.39–1.69)
 Model 2 ref 1.00 (0.85–1.16) 1.14 (0.95–1.32) 0.92 (0.73–1.11) 1.20 (1.03–1.36) 1.06 (0.93–1.20) 1.19 (1.04–1.34)
 Model 3 ref 0.99 (0.84–1.15) 1.12 (0.94–1.31) 0.92 (0.73–1.11) 1.16 (0.99–1.33) 1.06 (0.92–1.20) 1.18 (1.03–1.32)
 Model 4 ref 0.99 (0.83–1.14) 1.09 (0.90–1.28) 0.90 (0.71–1.09) 1.15 (0.98–1.31) 1.04 (0.90–1.18) 1.19 (1.04–1.34)
 Model 5 ref 1.00 (0.85–1.15) 1.10 (0.92–1.29) 0.83 (0.64–1.02) 1.10 (0.94–1.27) 1.10 (0.97–1.24) 1.15 (1.00–1.30)
 Model 6 ref 0.99 (0.85–1.15) 1.05 (0.86–1.23) 0.78 (0.59–0.97) 1.20 (1.04–1.37) 1.06 (0.92–1.20) 1.16 (1.01–1.31)
Lower femur fracture
 Model 1 ref 1.04 (0.60–1.49) 1.32 (0.78–1.87) 0.89 (0.37–1.40) 1.09 (0.55–1.63) 2.33 (1.93–2.72) 1.08 (0.63–1.52)
 Model 2 ref 1.05 (0.60–1.49) 1.38 (0.83–1.92) 0.63 (0.12–1.14) 0.95 (0.41–1.49) 2.13 (1.74–2.53) 0.97 (0.52–1.41)
 Model 3 ref 1.04 (0.60–1.49) 1.36 (0.82–1.91) 0.62 (0.10–1.13) 0.91 (0.37–1.45) 1.99 (1.59–2.39) 0.97 (0.52–1.42)
 Model 4 ref 1.03 (0.58–1.47) 1.29 (0.74–1.83) 0.59 (0.07–1.10) 0.88 (0.34–1.42) 1.89 (1.49–2.29) 0.99 (0.54–1.44)
 Model 5 ref 1.01 (0.57–1.46) 1.28 (0.73–1.82) 0.61 (0.09–1.12) 0.89 (0.34–1.43) 1.83 (1.43–2.23) 1.00 (0.55–1.45)
 Model 6 ref 1.04 (0.59–1.48) 1.36 (0.82–1.90) 0.68 (0.17–1.19) 1.01 (0.47–1.55) 2.14 (1.74–2.53) 0.99 (0.55–1.44)
Upper extremity or lower leg fracture
 Model 1 ref 1.17 (1.01–1.34) 1.16 (0.95–1.38) 0.97 (0.78–1.16) 1.18 (0.98–1.38) 1.82 (1.67–1.96) 1.95 (1.79–2.11)
 Model 2 ref 1.28 (1.11–1.44) 1.32 (1.11–1.53) 0.77 (0.58–0.96) 1.32 (1.11–1.53) 1.92 (1.77–2.07) 1.89 (1.73–2.05)
 Model 3 ref 1.28 (1.11–1.44) 1.31 (1.10–1.52) 0.78 (0.59–0.97) 1.11 (0.91–1.31) 1.93 (1.78–2.08) 1.87 (1.71–2.03)
 Model 4 ref 1.28 (1.11–1.45) 1.33 (1.12–1.54) 0.78 (0.59–0.97) 1.13 (0.93–1.33) 1.93 (1.78–2.08) 1.86 (1.70–2.02)
 Model 5 ref 1.27 (1.10–1.44) 1.32 (1.11–1.54) 0.80 (0.61–0.99) 1.14 (0.93–1.34) 1.90 (1.74–2.05) 1.87 (1.71–2.03)
 Model 6 Ref 1.26 (1.10–1.33) 1.33 (1.12–1.45) 0.76 (0.57–0.95) 1.26 (1.06–1.46) 1.87 (1.72–2.02) 1.88 (1.72–2.04)
Vertebral fracture
 Model 1 ref 0.91 (0.64–1.18) 1.08 (0.74–1.42) 0.77 (0.45–1.08) 1.99 (1.71–2.28) 1.15 (0.91–1.38) 1.42 (1.16–1.68)
 Model 2 ref 0.90 (0.63–1.17) 0.93 (0.59–1.28) 0.99 (0.68–1.31) 1.39 (1.10–1.67) 0.94 (0.70–1.18) 1.16 (0.90–1.43)
 Model 3 ref 0.90 (0.63–1.17) 0.92 (0.58–1.27) 0.99 (0.67–1.31) 1.36 (1.07–1.64) 0.94 (0.70–1.18) 1.16 (0.90–1.42)
 Model 4 ref 0.89 (0.62–1.16) 0.96 (0.64–1.28) 0.89 (0.55–1.24) 1.34 (1.05–1.63) 0.91 (0.67–1.15) 1.18 (0.92–1.44)
 Model 5 ref 0.89 (0.62–1.16) 0.90 (0.55–1.24) 0.94 (0.62–1.26) 1.33 (1.04–1.62) 0.92 (0.68–1.16) 1.17 (0.91–1.43)
 Model 6 Ref 0.90 (0.63–1.17) 0.94 (0.60–1.29) 0.92 (0.61–1.24) 1.47 (1.18–1.76) 0.94 (0.70–1.17) 1.22 (0.96–1.48)

Model 1: Cause of ESKD.

Model 2: Model 1 + demographic and socioeconomic characteristics, i.e. age, gender, race, Hispanic, region, socioeconomic status.

Model 3: Model 2 + clinical characteristics, i.e. comorbidities and dialysis modality.

Model 4: Model 3 + laboratory values, i.e. eGFR, hemoglobin and albumin.

Model 5: Model 4 + BMI.

Model 6: Model 1 + age, gender.

All models stratified by incidence year of ESKD.

Significant findings in bold (p < 0.05).